$ABIO Company is ran by the founder of Myogen, who in return sold Myogen for 2.5 billion to Gilead Sciences in back 2006. Arca has developed Gencaro(phase 2b) which is a therapy to treat A-fib. $ABIO has Medtronic and labcorp who are two very active partners. Gencaro has a 74% reduction in the prevention of A-fib. Phase 3 q1 '14, but a buyout may be coming.
On the technical side institutions have channeled PPS for 2 months and are stealth accumulating. This evident on L2 with bids exceeding 100k on most trading days. Just a matter of time when institutions have completed their position and will let this run. New trend has started with abnormal volume activity late last week.
Market Data 
Markets 
AI
